Avid Bioservices, Inc. (CDMO)
| Market Cap | 1.60B |
| Revenue (ttm) | 101.23M |
| Net Income (ttm) | 5.61M |
| Shares Out | 61.14M |
| EPS (ttm) | 0.11 |
| PE Ratio | 241.03 |
| Forward PE | 99.01 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 868,878 |
| Open | 25.13 |
| Previous Close | 24.82 |
| Day's Range | 24.76 - 26.47 |
| 52-Week Range | 6.99 - 28.36 |
| Beta | 2.24 |
| Analysts | Strong Buy |
| Price Target | 28.25 (+9.5%) |
| Est. Earnings Date | Dec 1, 2021 |
About CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides var...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for CDMO stock is "Strong Buy." The 12-month stock price forecast is 28.25, which is an increase of 9.54% from the latest price.
News
Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy
Leverages Established Track Record of Excellence in Biologics CGMP Manufacturing to Address the Rapidly Growing Cell and Gene Therapy Market
Dear SRNG Stock Fans, Mark Your Calendars for Ginkgo Bioworks' Debut on Sept. 17
Soaring Eagle Acquisition is about to complete its merger with Ginkgo Bioworks, and SRNG stock is reacting well. Here's why.
Down 20.1% in 4 Weeks, Here's Why Avid Bioservices (CDMO) Looks Ripe for a Turnaround
Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings esti...
Avid Bioservices Announces Appointment of Esther M. Alegria, Ph.D.
Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry Experience Former SVP of Global Manufacturing at Biogen Has Nearly 30 Years of Biopharmaceutical Industry E...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Develop...
-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 --
Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on J...
TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives ...
Avid Bioservices (CDMO) Q4 Earnings Preview: What's in the Cards?
Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
7 A-Rated Biotech Stocks to Buy Now
Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on Inves...
Avid Bioservices (CDMO) Stock Jumps 7.2%: Will It Continue to Soar?
Avid Bioservices (CDMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics' ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) ...
7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts
Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts appe...
Avid Bioservices' (CDMO) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Avid Bioservices, Inc. (CDMO).
Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock
TUSTIN, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to impr...
5 Stocks to Buy on New Analyst Coverage
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Interactive Brokers (IBKR), Avid (CDMO), Oncternal (ONCT), Amtech (ASYS) and Aytu.
Find Strong Stocks to Start Q2 with New Analyst Coverage
Find Strong Stocks to Start Q2 with New Analyst Coverage
These 5 Stocks Are Safe Bets Courtesy of New Analyst Coverage
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like UFP Industries (UFPI), Interactive Brokers (IBKR), Avid (CDMO), Amtech (ASYS) and GAIA
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improv...
Avid Bioservices (CDMO) Sees Hammer Chart Pattern: Time to Buy?
Avid Bioservices (CDMO) has been struggling lately, but the selling pressure may be coming to an end soon
Avid Bioservices, Inc. Announces Pricing of $125 Million Offering of Exchangeable Senior Notes
TUSTIN, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) w...
Avid Bioservices (CDMO) Surpasses Q3 Earnings and Revenue Estimates
Avid Bioservices (CDMO) delivered earnings and revenue surprises of 150.00% and 9.03%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for the stock?
Avid Bioservices, Inc. Announces Proposed $125 Million Offering of Exchangeable Senior Notes
TUSTIN, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) w...
Avid Bioservices: Q3 Earnings Insights
Shares of Avid Bioservices (NASDAQ:CDMO) increased in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 116.67% over the past year to $0.01, which bea...
Avid Bioservices Reports Financial Results for Third Quarter Fiscal 2021 and Recent Developments
-- Third Quarter Revenue Increased 61% to $21.8 Million -- -- S igned $74 Million in New Orders to End the Quarter with a Backlog of $120 Million --
Avid Bioservices Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
TUSTIN, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improv...
Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2021 After Market Close on March 8, 2021
TUSTIN, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improv...